Outcome analysis in patients with uterine sarcoma

Area of Science:

• Gynecologic Oncology
• Surgical Oncology
• Radiation Oncology

Background:

• Uterine sarcoma is a rare and aggressive malignancy.
• Radical surgery is the primary treatment modality.
• The role of adjuvant radiotherapy requires further clarification.

Purpose of the Study:

• To identify prognostic factors for survival in uterine sarcoma.
• To assess the impact of postoperative whole pelvic radiotherapy (WPRT) on pelvic failure.
• To stratify treatment based on histologic subtypes and failure patterns.

Main Methods:

• Retrospective analysis of 75 uterine sarcoma patients treated with radical surgery.
• Comparison between patients who received postoperative WPRT (n=22) and those who did not (n=53).
• Analysis of overall survival (OS) and pelvic failure-free survival (PFFS) with a median follow-up of 64 months.

Main Results:

• The 5-year OS and PFFS for all patients were 64.2% and 83.4%, respectively.
• Mitotic count was a significant predictor of OS (p=0.006).
• Postoperative WPRT significantly reduced pelvic failure in carcinosarcoma (10.0% vs. 53.7%, p=0.046) but not in non-carcinosarcoma (12.5% vs. 9.9%, p=0.866).

Conclusions:

• Mitotic count is the most significant predictor of overall survival.
• Postoperative WPRT benefits pelvic failure-free survival in carcinosarcoma, but not in other histologic subtypes.
• Adjuvant treatment strategies should be individualized based on histologic type and recurrence risk.